Web Desc
Engineering the Genome
joint with Emerging Cellular Therapies: Cancer and Beyond
Scientific Organizers: Vic Myer and Erik Sontheimer
Date: February 08 - 12, 2020
Location: Fairmont Banff Springs, Banff, AB, Canada
Sponsored by Editas Medicine and Novo Nordisk A/S
Summary of Meeting:
Genome editing is already transforming biological science and promises to do the same for human medicine. Technological capabilities are advancing rapidly and there are expected to be more than 30 genome editing therapies in clinical development by 2020. It is therefore important that practitioners in both academia and industry have the opportunity to learn about the latest improvements and applications. This conference will bridge that gap and provide an ideal environment for scientific exchange. In addition, participants will be educated on the growing roster and utility of genome engineering platforms. There will be sessions on genome editing’s clinical advancements and the evolution of thinking in the field regarding translational sciences. This meeting is being paired with Emerging Cellular Therapies so that participants can come together with researchers who focus on cell-based therapies. Therefore, we anticipate attendees will have a greater awareness of the full range of genome engineering tools, both established and emerging and knowledge of best practices and pitfalls in clinical advancement.
DEADLINES:
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Deadline: October 29 2019 details
Discounted Abstract Deadline: October 29 2019 details & pricing
Abstract Deadline: November 6 2019 details & pricing
Discounted Registration Deadline: December 10 2019 details & pricing


Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.


Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.


IT’S NOT TOO LATE TO SUBMIT YOUR ABSTRACT. Abstracts received can no longer be considered for short talks. Abstracts may be submitted for poster presentations up to 6 weeks prior to meeting start date based on availability


Keystone Symposia thanks our Sponsor for generously supporting this meeting:
Editas MedicineNovo Nordisk A/S
We gratefully acknowledge additional support from these exhibitors at this conference:
10x GenomicsBEX CO., LTD.Cellecta, Inc.Integrated DNA TechnologiesMilliporeSigma
We gratefully acknowledge additional support for this conference from:
AgilentIntellia Therapeutics
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Intellia Therapeutics
We gratefully acknowledge the generous grant for this conference provided by:

National Center for Advancing Translational Sciences (NCATS)
Grant No. 1R13TR003025-01
Funding for this conference was made possible (in part) by 1R13TR003025-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government. This award reflects support from the NIH Common Fund Somatic Cell Genome Editing (SCGE) program in the amount of $22,200 total costs.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found